

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



November 10, 2022

## Consolidated Financial Results for the Six Months Ended September 30, 2022 (Under Japanese GAAP)

Company name: Takara Bio Inc.  
 Listing: Tokyo Stock Exchange  
 Securities code: 4974  
 URL: <https://www.takara-bio.co.jp>  
 Representative: Koichi Nakao, President & CEO  
 Inquiries: Takuya Kakemi, Executive Officer, in charge of PR & IR Department

Telephone: +81-77-565-6970  
 Scheduled date to file quarterly securities report: November 11, 2022  
 Scheduled date to commence dividend payments: -  
 Preparation of supplementary material on quarterly financial results: Yes  
 Holding of quarterly financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

### 1. Consolidated financial results for the six months ended September 30, 2022 (from April 1, 2022 to September 30, 2022)

#### (1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Net income attributable to owners of the parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six months ended								
Sep. 30, 2022	32,587	3.3	10,870	(22.9)	10,955	(23.1)	8,538	(14.7)
Sep. 30, 2021	31,551	81.4	14,105	277.5	14,241	272.8	10,009	340.1

Note: Comprehensive income For the six months ended Sep. 30, 2022: ¥14,858 million; 19.9%  
 For the six months ended Sep. 30, 2021: ¥12,390 million; 670.4%

	Net income per share	Fully diluted net income per share
Six months ended	Yen	Yen
Sep. 30, 2022	70.91	-
Sep. 30, 2021	83.12	-

#### (2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	yen
Sep. 30, 2022	120,023	106,949	88.9	886.08
Mar. 31, 2022	115,712	96,064	82.9	796.18

Reference: Equity  
 As of Sep. 30, 2022: ¥106,697 million  
 As of Mar. 31, 2022: ¥95,873 million

## 2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended Mar. 31, 2022	-	0.00	-	33.00	33.00
Fiscal year ending Mar. 31, 2023	-	0.00			
Fiscal year ending Mar. 31, 2023 (Forecast)			-	40.00	40.00

Note: Revisions to the forecast of cash dividends most recently announced: Yes

## 3. Consolidated financial forecasts for the fiscal year ending March 31, 2023 (April. 1, 2022 – March. 31, 2023)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Net income attributable to owners of the parent		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
Full year	77,800	14.9	19,000	(34.3)	19,100	(32.9)	13,800	(30.5)	114.60

Note: Revisions to the financial forecast since the most recent announced: Yes

### \* Notes

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

Newly included: - companies (Company name)

Excluded: - companies (Company name)

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of Sep. 30, 2022	120,415,600 shares
As of Mar. 31, 2022	120,415,600 shares

(ii) Number of treasury shares at the end of the period

As of Sep. 30, 2022	- shares
As of Mar. 31, 2022	- shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended Sep. 30, 2022	120,415,600 shares
Six months ended Sep. 30, 2021	120,415,600 shares

\* Quarterly financial results reports are exempt from quarterly review conducted by certified public accountants or an audit corporation.

\* Proper use of financial forecasts, and other special matters

(Special note regarding forward-looking statements)

The forward-looking statements, including financial forecasts, contained in this document are determined by the Takara

Bio Inc. (the “Company”) based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to “1. Overview of Financial Results for the six months ended September 30, 2022 (4) Future Outlook on page 2 of the attached document.

## Contents of the attached document

1. Overview of Financial Results for the six months ended September 30, 2022.....	2
(1) Overview of Financial Results.....	2
(2) Overview of Financial Position.....	2
(3) Overview of Cash Flows.....	2
(4) Future Outlook.....	3
2. Consolidated Quarterly Financial Statements and Primary Notes.....	4
(1) Consolidated Quarterly Balance Sheets.....	4
(2) Consolidated Quarterly Statements of Profit or Loss and Comprehensive Income.....	6
(Consolidated Quarterly Statements of Profit or Loss).....	6
(Consolidated Quarterly Statements of Comprehensive Income).....	7
(3) Consolidated Quarterly Statements of Cash Flows.....	8
(4) Notes to Consolidated Quarterly Financial Statements.....	9
(Notes on Premise of Going Concern).....	9
(Notes in case of Changes in Marked Amount of Shareholders' Equity).....	9
(Additional Information).....	9
(Significant Subsequent Events).....	9
3. Supplementary Information.....	10
(1) Trends in Key Indicators for Business Management.....	10
(2) Comparative Consolidated Statement of Income.....	11
(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts.....	12

## 1. Overview of Financial Results for the six months ended September 30, 2022

### (1) Overview of Financial Results

The outlook for the global economy in the fiscal year under review is uncertain due to the impact of the new Coronavirus disease (COVID-19), the prolonged trade friction between the U.S. and China, and Russia's invasion of Ukraine.

Under these circumstances, Takara Bio Group is promoting initiatives to advance the development of fundamental biologics development technologies and become a biologics development company that continuously creates new modalities through Reagents and Instruments and CDMO business under the six-year Long-Term Management Plan FY2026, which ends in fiscal 2026, and the three-year Medium-Term Management Plan FY2023, which ends in fiscal 2023<sup>1</sup>. In addition, the Group worked aggressively to ensure a stable supply of testing-related products for the new Coronavirus and to establish a manufacturing system for regenerative medicine and other products.

In the fiscal year under review, although sales of Instruments and CDMO decreased year on year, sales of Reagents and Gene Therapy increased year on year. In particular, Reagents for general research increased, while Reagents related to the new Coronavirus test increased due to the impact of the 7<sup>th</sup> wave of COVID-19 in Japan. As a result, net sales increased to ¥32,587 million (up 3.3% year on year). Cost of sales increased to ¥10,562 million (up 31.1% year on year) due to changes in the sales mix, gross profit decreased to ¥22,025 million (down 6.3% year on year). Selling, general and administrative (SG&A) expenses were ¥11,154 million (up 18.8% year on year), mainly due to an increase in personnel expenses and R&D expenses. Operating profit was ¥10,870 million (down 22.9% year on year).

As a result of the decrease in operating profit, ordinary profit decreased to ¥10,955 million (down 23.1% year on year), income before income taxes and others decreased to ¥11,831 million (down 16.7% year on year), and net income attributable to owners of the parent decreased to ¥8,538 million (down 14.7% year on year).

From the first quarter of the fiscal year under review, due to a review of management classifications, sales of reagents and other products of GMP grade (for the manufacture of regenerative medicine products), which were previously included in Reagents, are included in Gene Therapy. As a result, net sales for the second quarter of the previous fiscal year have been reclassified based on the new classification. In the second quarter of the previous fiscal year, ¥977 million, which was included in Reagents, has been reclassified as Gene Therapy.

Since our group is a single segment, the disclosure by segment is omitted.

### (2) Overview of Financial Position

Total assets at the end of the second quarter under review were ¥120,023 million, it was an increase of ¥4,310 million from the end of the previous fiscal year. This was mainly due to increases of ¥3,332 million in cash and deposits and ¥2,573 million in property, plant and equipment mainly owing to the acquisition of our manufacturing facilities, despite a decrease of ¥1,453 million in note and accounts receivable-trade.

Total liabilities at the end of the second quarter under review were ¥13,073 million, it was a decrease of ¥6,574 million from the end of the previous fiscal year. This was mainly due to decreases of ¥3,341 million in accrued income taxes and ¥3,326 million in other current liabilities.

Total net assets at the end of the second quarter under review were ¥106,949 million, an increase of ¥10,884 million from the end of the previous fiscal year. This was mainly due to increases of ¥4,564 million in retained earnings and ¥6,238 million in foreign currency translation adjustment due to the yen's depreciation.

### (3) Overview of Cash Flows

Net cash provided by operating activities amounted to ¥8,672 million, a decrease of ¥1,242 million from the previous fiscal year. This was mainly due to balance between cash inflow from profit before income taxes and others of ¥11,831 million, decrease in trade receivables-trade of ¥2,055 million, depreciation and amortization of ¥1,962 million and cash outflow from income taxes paid of ¥6,093 million.

Net cash used in investing activities was minus ¥7,518 million, a decrease of ¥3,168 million from the previous fiscal year. This was mainly due to payments into time deposits of ¥5,527 million, purchase of property, plant and equipment and intangible assets of ¥3,076 million, and proceeds from withdrawal of time deposits of ¥792 million.

Net cash used in financing activities amounted to ¥4,034 million, an increase of ¥2,042 million from the previous fiscal year, mainly due to cash dividends paid of ¥3,965 million.

As a result of the above, the balance of cash and cash equivalents at the end of the second quarter under review, including the effect of exchange rate changes on cash and cash equivalents, decreased by ¥1,554 million from the end of the previous fiscal year to ¥20,606 million

---

<sup>1</sup> FY2026 and FY2023 refer to the fiscal year ending March 31, 2026 and 2023, respectively.

**(4) Future Outlook**

The financial forecast and dividend forecast announced in the financial results summary on May 12, 2022 have been revised. For details, please refer to “Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (Dividend Increase)” announced today (November 10, 2022).

For comparison of the revised consolidated financial forecasts with previous fiscal year’s results and the previous financial forecasts, please refer to the “Comparative Statement of Income Relating to Consolidated Financial Forecasts” on page 12.

## 2. Consolidated Quarterly Financial Statements and Primary Notes

### (1) Consolidated Quarterly Balance Sheets

(Millions of yen)

	As of Mar. 31, 2022	As of Sep. 30, 2022
<b>Assets</b>		
Current asset		
Cash and deposits	23,633	26,965
Notes and accounts receivable-trade	17,845	16,391
Merchandise and finished goods	18,966	18,591
Work in process	1,361	1,452
Raw materials and supplies	3,738	4,074
Other	2,637	1,939
Allowance for doubtful accounts	(40)	(43)
Total current assets	68,141	69,370
Non-current assets		
Property, plant and equipment		
Buildings and structures	23,553	25,580
Accumulated depreciation	(5,937)	(6,753)
Buildings and structures, net	17,615	18,826
Machinery, equipment and vehicles	7,626	8,175
Accumulated depreciation	(4,147)	(4,726)
Machinery, equipment and vehicles, net	3,479	3,448
Tools, furniture and fixtures	9,530	10,078
Accumulated depreciation	(5,516)	(6,089)
Tools, furniture and fixtures, net	4,014	3,989
Land	8,413	8,747
Construction in progress	1,519	2,570
Others	1,642	1,752
Accumulated depreciation	(287)	(366)
Others, net	1,355	1,385
Total Property, plant and equipment	36,395	38,968
Intangible assets		
Goodwill	6,309	7,186
Other	2,850	2,844
Total intangible assets	9,159	10,031
Investments and other assets		
Investments and other assets	2,015	1,651
Total investments and other assets	2,015	1,651
Total non-current assets	47,571	50,652
Total assets	115,712	120,023

(Millions of yen)

	As of Mar. 31, 2022	As of Sep. 30, 2022
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable-trade	1,959	1,686
Accrued income taxes	5,498	2,156
Provision	923	973
Other	8,999	5,672
Total current liabilities	17,380	10,488
Non-current liabilities		
Retirement benefit liabilities	788	788
Other	1,478	1,796
Total non-current liabilities	2,266	2,585
Total liabilities	19,647	13,073
<b>Net assets</b>		
Shareholders' equity		
Shareholders' equity	14,965	14,965
Capital surplus	32,893	32,893
Retained earnings	45,009	49,573
Total shareholders' equity	92,868	97,433
Accumulated other comprehensive income		
Foreign currency translation adjustment	3,208	9,447
Cumulative remeasurements of retirement benefit	(204)	(182)
Total accumulated other comprehensive income	3,004	9,264
Non-controlling interests	191	251
Total net assets	96,064	106,949
<b>Total liabilities and net assets</b>	<b>115,712</b>	<b>120,023</b>



**(2) Consolidated Quarterly Statements of Profit or Loss and Comprehensive Income****(Consolidated Quarterly Statements of Profit or Loss)****(Six Months Ended Sep. 30, 2022)**

(Millions of yen)

	Six months ended Sep. 30, 2021	Six months ended Sep. 30, 2022
Net sales	31,551	32,587
Cost of sales	8,056	10,562
Gross profit	23,495	22,025
SG&A expenses		
Employees' salaries and bonuses	2,411	2,758
Retirement benefit expenses	115	122
R&D expenses	2,659	3,853
Provision of allowance	451	433
Other	3,752	3,986
Total SG&A expenses	9,389	11,154
Operating profit	14,105	10,870
Non-operating income		
Interest income	65	65
Foreign exchange gains	36	-
Rent income from real estate	65	72
Other	11	33
Total non-operating income	179	170
Non-operating expense		
Interest expenses	11	12
Foreign exchange loss	-	38
Rent expenses on real estate	29	32
Other	1	1
Total non-operating expenses	43	85
Ordinary profit	14,241	10,955
Extraordinary gains		
Gain on sale of fixed assets	0	250
Insurance received	-	652
National subsidies	1,188	-
Total extraordinary profit	1,188	902
Extraordinary losses		
Loss of sales on non-current assets	38	12
Asset shrinkage losses	1,188	-
Others	-	14
Total extraordinary losses	1,227	27
Profit before income taxes and others	14,203	11,831
Income taxes-current	4,401	2,538
Income taxes-deferred	(253)	721
Total income taxes	4,148	3,259
Net income	10,054	8,572
Net income attributable to non-controlling interest	45	33
Net income attributable to owners of the parent	10,009	8,538

**(Consolidated Quarterly Statements of Comprehensive Income)**  
**(Six Months Ended Sep. 30, 2022)**

(Millions of yen)

	Six months ended Sep. 30, 2021	Six months ended Sep. 30, 2022
Net income	10,054	8,572
Other comprehensive income		
Foreign currency translation adjustment	2,312	6,264
Remeasurements of retirement benefit	23	21
Total other comprehensive income	2,335	6,286
Comprehensive income	12,390	14,858
Comprehensive income attributable to:		
Owners of the parent	12,337	14,798
Non-controlling interest	53	59

**(3) Consolidated Quarterly Statements of Cash Flows**

(Millions of yen)

	Six months ended Sep. 30, 2021	Six months ended Sep. 30, 2022
Net cash provided by (used in) operating activities		
Profit before income taxes and others	14,203	11,831
Depreciation and amortization	1,670	1,962
Depreciation and amortization on other	46	35
Amortization of goodwill	245	280
Increase (decrease) in allowance for doubtful accounts	(3)	(20)
Increase (decrease) in other provision	72	(22)
Increase (decrease) in retirement benefit liabilities	(7)	(1)
Interest income	(65)	(65)
Interest expenses	11	12
Insurance claim income	-	(652)
Loss (gain) on sale and retirement of fixed assets	38	(238)
Decrease (increase) in trade receivables-trade	(766)	2,055
Decrease (increase) in inventories	(1,076)	960
Increase (decrease) in notes and accounts payable-trade	(621)	(615)
Increase (decrease) in other current liabilities	(834)	(1,965)
Other	119	513
Subtotal	13,033	14,070
Interest and dividend income received	76	55
Income expenses paid	(11)	(13)
Income taxes paid	(3,854)	(6,093)
Proceeds from insurance income	-	652
Subsidies received	671	-
Net cash provided by (used in) operating activities	9,914	8,672
Net cash provided by (used in) investing activities		
Payments into time deposits	(10,340)	(5,527)
Payments into time deposits	1,702	792
Purchase of property, plant and equipment and intangible assets	(5,367)	(3,076)
Proceeds from sales of property, plant and equipment and intangible assets	0	394
Purchase of other depreciable assets	(28)	(111)
Subsidies received	3,349	-
Other	(1)	10
Net cash provided by (used in) investing activities	(10,686)	(7,518)
Net cash provided by (used in) financing activities		
Dividends paid	(1,922)	(3,965)
Repayments of lease obligations	(69)	(69)
Net cash provided by (used in) financing activities	(1,992)	(4,034)
Effect of exchange rate change on cash and cash equivalents	568	1,325
Net increase (decrease) in cash and cash equivalents	(2,195)	(1,554)
Cash and cash equivalents at beginning of period	23,308	22,160
Cash and cash equivalents at end of period	21,113	20,606

#### **(4) Notes to Consolidated Quarterly Financial Statements**

##### **(Notes on Premise of Going Concern)**

No items to report.

##### **(Notes in case of Changes in Marked Amount of Shareholders' Equity)**

No item to report.

##### **(Additional Information)**

###### **(Accounting Estimates for the Impact of the COVID-19)**

No material changes have been made to the assumptions used in the previous fiscal year, including the future spread and timing of convergence of the COVID-19.

##### **(Significant Subsequent Events)**

###### **(Termination of the Agreement)**

At a meeting of the Board of Directors held on November 10, 2022, the Company resolved to terminate the agreement for the co-development and sales of NY-ESO-1 siTCR with Otsuka Pharmaceutical Co., Ltd. (the "agreement"), and the agreement was terminated on the same date upon mutual consent with Otsuka Pharmaceutical Co., Ltd. (Otsuka).

###### **(1) Reason for the agreement termination**

In collaboration with Otsuka, the Company had been developing NY-ESO-1 siTCR<sup>TM</sup> gene therapy product (the "product") in Japan and preparing for an application for marketing authorization. After a comprehensive review of policies and strategies related to the product by both companies, the Company and Otsuka agreed to terminate the agreement. This judgement is not due to any problem with the efficacy and safety of the product.

###### **(2) Name of the counterparty to the agreement**

Otsuka Pharmaceutical Co., Ltd.

###### **(3) Date of the agreement termination**

November 10, 2022

###### **(4) Details of the agreement**

- The Company and Otsuka co-develop the product in Japan.
- The Company grants Otsuka exclusive rights to market the product domestically for all indications and first refusal rights in nine Asian countries. The Company receive an upfront payment, milestone payments based on the progress of development. After the launch, the Company will receive lump-sum payments based on the achievement of certain running royalties and sales targets linked to net sales.
- The Company retains the rights to manufacture the product for clinical trials and the further commercialization and supply Otsuka on a chargeable basis.

###### **(5) Significant impact of the termination on business activities**

The technology, intellectual property and other rights related to the product licensed to Otsuka upon termination of the agreement will be returned to the Company. The milestone payments, lump-sum payments and the sales revenues on the further commercial supply will not occur.

### 3. Supplemental Information

#### (1) Trends in Key Indicators for Business Management

##### 1) Cash Flows

(Millions of yen)

	Six months ended Sep. 30, 2021 (Apr. 1, 2021 – Sep. 30, 2021)	Six months ended Sep. 30, 2022 (Apr. 1, 2022 – Sep. 30, 2022)	Year ended Mar. 31, 2022 (Apr. 1, 2021 – Mar. 31, 2022)
Cash flow from operating activities	9,914	8,672	6,985
Cash flow from investing activities	(10,686)	(7,518)	(7,071)
Cash flow from financing activities	(1,992)	(4,034)	(2,070)

##### 2) Sales Breakdown by Region

(Millions of yen)

	Six months ended Sep. 30, 2021 (Apr. 1, 2021 – Sep. 30, 2021)	Six months ended Sep. 30, 2022 (Apr. 1, 2022 – Sep. 30, 2022)	Year ended Mar. 31, 2022 (Apr. 1, 2021 – Mar. 31, 2022)
Japan	15,439	16,298	34,076
United States	4,548	6,263	10,186
China	5,472	5,388	11,908
Asia excluding Japan and China	3,450	1,860	6,614
Europe	2,526	2,643	4,668
Others	113	132	244
Total	31,551	32,587	67,699

**(2) Comparative Consolidated Statement of Income**

(Rounded down to one million yen)

	Six months ended Sep. 30, 2021	Six months ended Sep. 30, 2022	Y/Y change	Y/Y ratio
(Net sales)				
Reagents	24,988	27,565	2,576	10.3%
Instruments	712	694	(17)	(2.5%)
CDMO	4,732	3,183	(1,548)	(32.7%)
Gene Therapy	1,117	1,144	26	2.3%
Total net sales	31,551	32,587	1,035	3.3%
(Operating profit and Loss)				
<b>Net sales</b>	31,551	32,587	1,035	3.3%
Cost of sales	8,056	10,562	2,505	31.1%
Gross profit	23,495	22,025	(1,470)	(6.3%)
SG & A expenses	9,389	11,154	1,764	18.8%
Transportation expenses	406	330	(75)	(18.6%)
Advertising expenses	28	21	(6)	(23.0%)
Promotion expenses	305	306	1	0.3%
R&D expenses	2,659	3,853	1,193	44.9%
Administrative expense, other	5,714	6,412	698	12.2%
Enterprise taxes (external standards taxation)	275	229	(45)	(16.7%)
<b>Operating profit</b>	14,105	10,870	(3,234)	(22.9%)
(Non-operating income and Expenses)				
Non-operating income	179	170	(8)	(4.8%)
Non-operating expenses	43	85	42	97.4%
<b>Ordinary profit</b>	14,241	10,955	(3,285)	(23.1%)
(Extraordinary income & Losses)				
Extraordinary income	1,188	902	(286)	(24.1%)
Extraordinary losses	1,227	27	(1,200)	(97.8%)
Income before income taxes and others	14,203	11,831	(2,371)	(16.7%)
Income taxes	4,148	3,259	(888)	(21.4%)
Net income	10,054	8,572	(1,482)	(14.7%)
Net income (loss) attributable to non-controlling interests	45	33	(12)	(26.5%)
<b>Net income attributable to owners of the parent</b>	10,009	8,538	(1,470)	(14.7%)

Depreciation and amortization (Property, plant and equipment and intangible assets)	1,670	1,962	291	17.4%
Amortization of goodwill	245	280	34	14.2%

※ The sales of GMP-grade reagents included in "Reagents" until the year ended of March 31, 2022 have been included in "Gene Therapy" since the year ending March 31, 2023. The result for the year ended Mar. 31, 2022 in this table have been reclassified to reflect these changes.

### (3) Comparative Statement of Income Relating to Consolidated Financial Forecasts

(Rounded down to one million yen)

	Year ended Mar. 31, 2022 Actual	Year ending Mar. 31, 2023		Y/Y Change	Y/Y Ratio	Previous forecast Change	Previous forecast Ratio
		Previous forecast	Current forecast				
(Net sales)							
Reagents	52,479	41,010	65,106	12,626	24.1%	24,095	58.8%
Instruments	1,518	1,471	1,716	197	13.0%	244	16.6%
CDMO	11,426	10,212	8,356	(3,070)	(26.9%)	(1,855)	(18.2%)
Gene Therapy	2,275	2,606	2,621	346	15.2%	15	0.6%
<b>Total Net Sales</b>	<b>67,699</b>	<b>55,300</b>	<b>77,800</b>	<b>10,100</b>	<b>14.9%</b>	<b>22,500</b>	<b>40.7%</b>
(Operating profit and Loss)							
<b>Net sales</b>	<b>67,699</b>	<b>55,300</b>	<b>77,800</b>	<b>10,100</b>	<b>14.9%</b>	<b>22,500</b>	<b>40.7%</b>
Cost of sales	18,488	17,444	34,068	15,580	84.3%	16,624	95.3%
Gross profit	49,211	37,855	43,731	(5,480)	(11.1%)	5,875	15.5%
SG & A expenses	20,309	22,855	24,731	4,421	21.8%	1,875	8.2%
Transportation expenses	755	748	667	(88)	(11.7%)	(81)	(10.9%)
Advertising expenses	58	91	51	(6)	(11.8%)	(39)	(43.8%)
Promotion expenses	683	899	729	45	6.7%	(169)	(18.9%)
R&D expenses	6,109	7,820	8,713	2,604	42.6%	893	11.4%
Administrative expenses, other	12,153	12,877	14,118	1,964	16.2%	1,241	9.6%
Enterprise taxes (external standards taxation)	548	418	450	(97)	(17.8%)	31	7.6%
<b>Operating profit</b>	<b>28,902</b>	<b>15,000</b>	<b>19,000</b>	<b>(9,902)</b>	<b>(34.3%)</b>	<b>4,000</b>	<b>26.7%</b>
(Non-operating income and Expenses)							
Non-operating income	357	211	244	(113)	(31.7%)	32	15.5%
Non-operating expenses	800	111	144	(655)	(82.0%)	32	29.4%
<b>Ordinary profit</b>	<b>28,459</b>	<b>15,100</b>	<b>19,100</b>	<b>(9,359)</b>	<b>(32.9%)</b>	<b>4,000</b>	<b>26.5%</b>
(Extraordinary gains & Losses)							
Extraordinary gains	4,476	250	902	(3,573)	(79.8%)	652	260.9%
Extraordinary losses	5,403	55	75	(5,328)	(98.6%)	19	35.2%
Income before income taxes and others	27,532	15,294	19,927	(7,605)	(27.6%)	4,632	30.3%
Income taxes	7,624	4,648	6,102	(1,522)	(20.0%)	1,453	31.3%
Net income	19,908	10,645	13,825	(6,082)	(30.6%)	3,179	29.9%
Net income (loss) attributable to non- controlling interests	58	45	25	(33)	(56.9%)	(20)	(45.1%)
<b>Net income attributable to owners of parent</b>	<b>19,849</b>	<b>10,600</b>	<b>13,800</b>	<b>(6,049)</b>	<b>(30.5%)</b>	<b>3,200</b>	<b>30.2%</b>
Depreciation and amortization (Property, plant and equipment and intangible assets)	3,554	4,282	4,207	652	18.3%	(75)	(1.8%)
Amortization of goodwill	500	514	599	99	19.9%	85	16.6%

※ The sales of GMP-grade reagents included in "Reagents" until the year ended of March 31, 2022 have been included in "Gene Therapy" since the year ending March 31, 2023. The results for the year ended Mar. 31, 2022 in this table have been reclassified to reflect these changes.